by div write | May 20, 2025 | Downgrades
Wells Fargo has lowered its rating on Westlake Corporation from ‘Overweight’ to ‘Equal Weight’, citing deteriorating market conditions in the commodity chemicals sector. The firm also trimmed its price target from \$95 to \$76, reflecting...
by div write | May 20, 2025 | Downgrades
Jefferies has lowered its rating on AES Corp. from “Hold” to “Underperform,” cutting the price target to \$9. This shift follows a sharp 15% rally in the stock, spurred by optimism around a newly proposed tax bill. However, analysts are cautioning that this bump in...
by div write | May 15, 2025 | Downgrades
Oppenheimer has revised its rating on Ares Management (ARES) from “Outperform” to “Perform,” pointing to concerns that the stock’s valuation has outpaced its earnings potential. While Ares continues to deliver solid financials, the downgrade...
by div write | May 14, 2025 | Downgrades
UnitedHealth Group (NYSE: UNH) is under heavy investor scrutiny following back-to-back downgrades and a significant plunge in share price. Once a staple of stability in the healthcare sector, the stock has tumbled nearly 40% year-to-date, now among the worst...
by div write | May 14, 2025 | Downgrades
KeyBanc Capital Markets has downgraded Portland General Electric (NYSE: POR) from Overweight to Sector Weight, citing jurisdictional challenges that could impact the company’s regulatory environment and growth prospects. Despite a 16.4% increase in industrial...
by div write | May 14, 2025 | Downgrades
Citigroup has downgraded Merck & Co. from “Buy” to “Neutral,” with a revised price target of \$84. This move centers on the looming 2028 loss of exclusivity for Merck’s cornerstone cancer drug, Keytruda. Though the market has partially...
